We found the high COX-2 group in GC presented lower drug sensitivity to Gefitinib, Afatinib, Erlotinib, XAV939, AZD1332, Sapitinib, Wnt-C59, CDK9, Ibrutinib, AZD3795, Osimertinib and P22077 (Figure 3D). This evidence concerns the gene PTGS2 and gastric cancer.